

image

1631

Attorney Docket No.: 5559.204-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bojsen et al.

Confirmation No: To Be Assigned

Serial No.: 09/856,819

Group Art Unit: To Be Assigned

Filed: May 24, 2001

Examiner: To Be Assigned

For: Lipolytic Enzyme Variants

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO/SB/08A
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to the address indicated above on February 6, 2004.

Julie Tabarovsky  
(name of person mailing paper)

Julie Tabarovsky  
(signature of person mailing paper)



Attorney Docket No.: 5559.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bojsen et al.

Confirmation No: To Be Assigned

Serial No.: 09/856,819

Group Art Unit: To Be Assigned

Filed: May 24, 2001

Examiner: To Be Assigned

For: Lipolytic Enzyme Variants

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed. It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.


This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: February 6, 2004

Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

PTO/SB/08A (10-01)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/856,819		
		Filing Date	May 24, 2001		
		First Named Inventor	Bojsen et al.		
		Art Unit	To Be Assigned		
		Examiner Name	To Be Assigned		
Sheet	2	of	2	Attorney Docket Number	5559.204-US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Kampen et al., Chemistry and Physics of Lipids, Vol. 93, pp. 39-45, (1998)	
		Joerger et al., Lipids, Vol. 29, No. 6, pp. 377-384, (1994)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.